Recent studies show that a potential Alzheimer’s pandemic could potentially bankrupt the United States Healthcare system. However, the successful development of a disease-modifying drug for Alzheimer’s could potentially save the U.S. Healthcare system an estimated $4.0 trillion dollars. Building off of the success of our inaugural conference, CBI’s Second Annual Alzheimer’s Drug Development Summit examines the latest disease modifying therapies and pre-symptomatic approaches for Alzheimer’s.

Hear Three Case Studies on the Latest AD Treatment Initiatives:

An update on the development of CTS21166 an Oral Beta Secretase Inhibitor
Data that supports the notion of a metabolic subtype of AD patients
Description of the aims and structure of the Alzheimer’s Disease Neuroimaging Initiative (ADNI)


Hear what some of our previous attendees had to say:



“This conference gave me a very good understanding of where we are in terms of Alzheimer’s Disease.”
– Baldeo Taneja, Sr. Manager, Biostatistics, EPIX Pharma

“CBI assembled a terrific cast of presenters covering the breadth of an exciting time where new treatments for Alzheimer’s disease and the science underlying them is maturing.”
-- Stevin Zorn, AD Team Leader, Pfizer

“Well put-together meeting with relevant topics.” – Tom Zoda, Executive Director, PPD

“The conference was well presented tying many disciplines into one common theme allowing everybody to hear about the other aspects of AD research.” – David Cash, Senior Scientist, IXICO

“The two-day conference was packed with relevant presentations and networking opportunities – it was very worthwhile.” – Suzanne Hendrix, Director of Strategic Development, Myriad Pharmaceuticals

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.